HomeBody MapPeptidesCalculator
Catalog4 refs

Leuprolide

OtherResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Half-life
4
Uses
Variable -
Typical
Body Map
Loading 3D model…
Overview

Leuprolide is a superagonist at the pituitary GnRH receptor. When you first give it, it strongly stimulates the receptor and causes a transient surge in LH, FSH, and sex hormones, the so-called flare. With continuous exposure, the pituitary internalizes and downregulates its GnRH receptors and becomes desensitized, so within roughly two to four weeks LH and FSH plummet and gonadal testosterone or estrogen falls to near-castrate levels. In prostate cancer, removing testosterone starves androgen-dependent tumor cells; in endometriosis and fibroids, dropping estrogen shrinks hormone-driven tissue and eases pain.

Primary Uses
advanced prostate cancer
endometriosis
uterine fibroids
central precocious puberty
Protocol Reference
Dose
Variable - depends on formulation. Range: 1 mg daily to 45 mg every 6 months. FDA-approved dosing includes 7.5mg monthly depot, 22.5mg 3-month depot, and 45mg 6-month depot.
Frequency
Daily, monthly, or every 3-6 months
Route
Intramuscular depot injection · Subcutaneous depot injection
Evidence
FDA Approved
Research References· 2
FDA Approved Labeling \- Prescribed dose ↗
PubMedPMID 296021022.5mg 3-month depot
https://pubmed.ncbi.nlm.nih.gov/17970643/
PubMedPMID 17970643### Research This Peptide Further
Research Models
Human
Also in Other
Other
Abaloparatide
Osteoporosis treatment · Postmenopausal Osteoporosis
Other
ACE-031
Muscle Hypertrophy · Muscular Dystrophy
Other
ACTH (Cosyntropin)
Diagnostic tool to test adrenal gland function · Assess adrenal reserve
Other
Adrenocorticotropic hormone (ACTH)
adrenal insufficiency diagnosis · adrenal insufficiency treatment
Compare